Br J Ophthalmol:携带HTLV-1的葡萄膜炎患者系统性疾病研究!

2017-07-11 cuiguizhong MedSci原创

日本鹿儿岛大学医学与牙科学研究科眼科系的Sakamoto T教授近日在Br J Ophthalmol上发表了一项他们最近的工作,对HTLV-1携带者的引发的葡萄膜炎的系统性疾病进行了研究!

日本鹿儿岛大学医学与牙科学研究科眼科系的Sakamoto T教授近日在Br J Ophthalmol上发表了一项他们最近的工作,对HTLV-1携带者的引发的葡萄膜炎的系统性疾病进行了研究!

人T淋巴细胞1型病毒(HTLV-1)携带者可能会出现严重的全身性疾病,如成人T细胞白血病(ATL)或HTLV-1相关性脊髓病/热带痉挛性截瘫(HAM / TSP)。他们在文章中探讨HTLV-1引起葡萄膜炎(HAU)的HTLV-1携带者的全身疾病。他们调查了200例HAU患者的全身疾病发生情况,对其病历进行了回顾性调查,并对邮寄调查结果进行了筛查

他们发现,1627例HAU中,HAU发病的平均年龄为49岁。他们研究了2例ATL。其中一例在HAU发病时被诊断为发低烧的ATL,另一例在HAU发病4年后发生急性ATL。共有26例HAM / TSP,其中HAM / TSP首发13例,HAU首次发生11例。 HAM / TSP和HAU发病间隔6个月至6年。HAM / TSP或HAU哪个首先发生并无显着性差异。所有情况下,甲状腺功能亢进症45例,发病前均有记录。在开始噻唑唑治疗后出现HAU的病例中,有两例在每次重新开始治疗后HAU复发。

因此,他们认为, HTLV-1的携带者引发的HAU比一般HAU患者具有更高的频率发生HAM / TSP。接受甲状腺功能亢进治疗的HTLV-1携带者也容易发生HAU。

原文出处:

Nakao K, Abematsu N, Sakamoto T.Systemic diseases in patients with HTLV-1-associated uveitis. Br J Ophthalmol. 2017 Jul 8. pii: bjophthalmol-2017-310658. doi: 10.1136/bjophthalmol-2017-310658

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993708, encodeId=f18a1993e0833, content=<a href='/topic/show?id=754991e9f6' target=_blank style='color:#2F92EE;'>#HTLV-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9179, encryptionId=754991e9f6, topicName=HTLV-1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Wed Dec 06 10:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016978, encodeId=309220169e8bf, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 10:06:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070413, encodeId=dce220e0413ea, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Sep 29 00:06:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541236, encodeId=34dc15412365d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 13 13:06:00 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1993708, encodeId=f18a1993e0833, content=<a href='/topic/show?id=754991e9f6' target=_blank style='color:#2F92EE;'>#HTLV-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9179, encryptionId=754991e9f6, topicName=HTLV-1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Wed Dec 06 10:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016978, encodeId=309220169e8bf, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 10:06:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070413, encodeId=dce220e0413ea, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Sep 29 00:06:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541236, encodeId=34dc15412365d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 13 13:06:00 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1993708, encodeId=f18a1993e0833, content=<a href='/topic/show?id=754991e9f6' target=_blank style='color:#2F92EE;'>#HTLV-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9179, encryptionId=754991e9f6, topicName=HTLV-1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Wed Dec 06 10:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016978, encodeId=309220169e8bf, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 10:06:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070413, encodeId=dce220e0413ea, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Sep 29 00:06:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541236, encodeId=34dc15412365d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 13 13:06:00 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1993708, encodeId=f18a1993e0833, content=<a href='/topic/show?id=754991e9f6' target=_blank style='color:#2F92EE;'>#HTLV-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9179, encryptionId=754991e9f6, topicName=HTLV-1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Wed Dec 06 10:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016978, encodeId=309220169e8bf, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 10:06:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070413, encodeId=dce220e0413ea, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Sep 29 00:06:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541236, encodeId=34dc15412365d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 13 13:06:00 CST 2017, time=2017-07-13, status=1, ipAttribution=)]

相关资讯

PLoS One:中枢浆液脉络膜视网膜病变中的系统性补体激活

荷兰莱顿大学医学中心眼科系的Boon CJF团队近日在PLoS One上发表了他们的一项新的研究,他们研究了中枢浆液脉络膜视网膜病变中的系统性补体激活情况。

Int Ophthalmol.:使用在平衡盐溶液中加有0.025%聚维酮碘的囊袋进行灌洗可以治疗术后眼内炎症!

日本长野大久保眼科诊所的 Okubo H近日在Int Ophthalmol上发表了他们最近的一项工作,探索了在手术后,可以用加有0.025%聚维酮碘的平衡盐溶液囊袋进行灌洗,治疗术后眼内炎症。

机器人“医生”AI查眼病 广州首推人工智能门诊

广州中山眼科中心推出的全球首个 “眼科人工智能(AI)诊疗”正式向公众开放,在探索人工智能的临床应用方面迈出第一步。

Br J Ophthalmol. :Leber先天性黑斑和早发性严重视网膜营养不良:临床特征、分子遗传学和治疗干预综述!

英国伦敦伦敦大学学院眼科学研究所的Michaelides M教授近日在Br J Ophthalmol上发表了一篇综述,对Leber先天性黑斑和早发性严重视网膜营养不良在临床诊断特征、病理生理学特征、动物模型和人类治疗研究等方面进行了详细的讨论。

PLoS One:中国东部儿科白内障手术的视觉恢复结果调查

山东大学附属山东省医院眼科的Guo J团队近日在PLoS One发表了他们的一项工作,他们调查了中国东部儿科白内障手术的视觉效果。

Ophthalmic Res:中枢性糖尿病性黄斑病变患者中双眼定视降低较差眼睛的固定眼动

丹麦奥胡斯奥胡斯大学医院眼科系的Jakobsen NS近日在Ophthalmic Res发表了他们最近的一项工作,他们比较了糖尿病性黄斑病变患者在单眼定视和双眼定视时眼动的差别,发现双眼定视降低较差眼睛的固定眼动。